Biotica Consolidates Leadership in Polyketide Therapeutics and Extends Platform

CAMBRIDGE, England--(BUSINESS WIRE)-- Biotica announces its consolidation of the polyketide engineering intellectual property (IP) space, via acquisition of IP from Bristol-Myers Squibb Company (NYSE:BMY). Combined with Biotica’s existing IP and proprietary know-how, this acquisition confirms Biotica’s leading position in polyketide therapeutics, a biologically rich and broadly applicable class of drugs.

The acquired IP originated from Stanford and Harvard Universities and Kosan Pharmaceuticals (acquired by Bristol-Myers Squibb in 2008). It gives Biotica access to complementary bioengineering techniques for use in lead optimisation and provides additional product opportunities in new polyketide chemical classes. The new IP also significantly enhances Biotica’s capabilities in manufacturing development through use of heterologous expression systems, with potential for reducing cost of goods and development time.

In addition to this IP acquisition, Biotica has extended its platform by building a proprietary library of naturally-occurring polyketides. These compounds are uniquely able to address major clinical unmet need, having inherent biological activity, often against targets that are difficult to modulate using traditional synthetic small molecules. With its growing library and expanded technology platform, Biotica is uniquely positioned to identify, optimise and manufacture polyketide therapeutics.

Edward Hodgkin, Chief Executive Officer of Biotica, said “Consolidating the Kosan IP with Biotica’s is a fundamental strategic move for us. We believe we are now the only company able to exploit the enormous potential of the polyketide opportunity.”

Notes to editors:
About Biotica
Biotica is a privately-held biotechnology company that discovers and develops polyketide therapeutics. It has a growing pipeline of novel therapeutic programmes supported by clinical validation. These include nPT-mTOR (unique mTOR inhibitors partnered with Pfizer), nPT-CLN (potent calcineurin inhibitors for inhaled use in asthma), nPT-CyP (cyclophilin inhibitors for HCV) and nPT-ery (anti-inflammatory erythromycin analogues partnered with GlaxoSmithKline). All of Biotica’s projects employ its proprietary novoPT™ technology, which enables it to select from the many known polyketides with biological activity and make a range of derivatives that are either difficult or impossible to make by medicinal chemistry methods. For additional information visit www.biotica.com.



CONTACT:

College Hill Life Sciences
Adam Michael, Gemma Howe
Tel: + 44 20 7866 7860
[email protected]

KEYWORDS:   United Kingdom  United States  Europe  North America

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Infectious Diseases  Optical  Pharmaceutical  Diabetes

MEDIA:

Logo
 Logo

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.